Apremilast in benign chronic pemphigus (Hailey–Hailey disease)
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2020-08, Vol.45 (6), p.737-739 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 739 |
|---|---|
| container_issue | 6 |
| container_start_page | 737 |
| container_title | Clinical and experimental dermatology |
| container_volume | 45 |
| creator | Riquelme‐Mc Loughlin, C. Iranzo, P. Mascaró, J.M. |
| description | |
| doi_str_mv | 10.1111/ced.14225 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2422938947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2422938947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3205-a2e738b6528d13d11aa3b7a789fa4b8f404acaf64e4b09a419bb9a38bb56abf03</originalsourceid><addsrcrecordid>eNqNkMtKAzEUhoMotlYXvoAMuLHItLnOZWcZqxUKbnQdkplMm9JmxmQG6c538A19ElOndSeYTQ7h-0_O-QC4RHCE_BnnqhghijE7An1EIhZiTOAx6EMC4zBKSdIDZ86tIEQExewU9AhGaZJS1gd3k9qqjV4L1wTaBFIZvTBBvrSV0XlQq0291IvWBTczoddq-_Xx2RVBoZ0STg3PwUkp1k5d7O8BeH2YvmSzcP78-JRN5mFOMGShwComiYwYTgpECoSEIDIWcZKWgsqkpJCKXJQRVVTCVFCUSpkKn5AsErKEZACuu761rd5a5Rq-qlpr_Jcc-9X9kimNPTXsqNxWzllV8trqjbBbjiDfueLeFf9x5dmrfcdWbvzrgTzI8UDSAe9KVqXLtTK5-sUghIxQwiLqK4gy3YhGVyarWtP46O3_o54e7-md2r9H5tn0vpv9G0twk1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2422938947</pqid></control><display><type>article</type><title>Apremilast in benign chronic pemphigus (Hailey–Hailey disease)</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Alma/SFX Local Collection</source><creator>Riquelme‐Mc Loughlin, C. ; Iranzo, P. ; Mascaró, J.M.</creator><creatorcontrib>Riquelme‐Mc Loughlin, C. ; Iranzo, P. ; Mascaró, J.M.</creatorcontrib><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/ced.14225</identifier><identifier>PMID: 32198945</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Adult ; Autoimmune diseases ; Chronic Disease ; Dermatology ; Female ; Follow-Up Studies ; Humans ; Life Sciences & Biomedicine ; Male ; Middle Aged ; Pemphigus ; Pemphigus, Benign Familial - drug therapy ; Pemphigus, Benign Familial - genetics ; Pemphigus, Benign Familial - pathology ; Phosphodiesterase 4 Inhibitors - administration & dosage ; Phosphodiesterase 4 Inhibitors - adverse effects ; Phosphodiesterase 4 Inhibitors - therapeutic use ; Quality of Life ; Science & Technology ; Severity of Illness Index ; Skin diseases ; Thalidomide - administration & dosage ; Thalidomide - adverse effects ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use ; Treatment Outcome</subject><ispartof>Clinical and experimental dermatology, 2020-08, Vol.45 (6), p.737-739</ispartof><rights>2020 British Association of Dermatologists</rights><rights>Copyright © 2020 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>9</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000534356400001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c3205-a2e738b6528d13d11aa3b7a789fa4b8f404acaf64e4b09a419bb9a38bb56abf03</citedby><cites>FETCH-LOGICAL-c3205-a2e738b6528d13d11aa3b7a789fa4b8f404acaf64e4b09a419bb9a38bb56abf03</cites><orcidid>0000-0001-5385-127X ; 0000-0001-9327-2555</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932,28255</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32198945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riquelme‐Mc Loughlin, C.</creatorcontrib><creatorcontrib>Iranzo, P.</creatorcontrib><creatorcontrib>Mascaró, J.M.</creatorcontrib><title>Apremilast in benign chronic pemphigus (Hailey–Hailey disease)</title><title>Clinical and experimental dermatology</title><addtitle>CLIN EXP DERMATOL</addtitle><addtitle>Clin Exp Dermatol</addtitle><subject>Adult</subject><subject>Autoimmune diseases</subject><subject>Chronic Disease</subject><subject>Dermatology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pemphigus</subject><subject>Pemphigus, Benign Familial - drug therapy</subject><subject>Pemphigus, Benign Familial - genetics</subject><subject>Pemphigus, Benign Familial - pathology</subject><subject>Phosphodiesterase 4 Inhibitors - administration & dosage</subject><subject>Phosphodiesterase 4 Inhibitors - adverse effects</subject><subject>Phosphodiesterase 4 Inhibitors - therapeutic use</subject><subject>Quality of Life</subject><subject>Science & Technology</subject><subject>Severity of Illness Index</subject><subject>Skin diseases</subject><subject>Thalidomide - administration & dosage</subject><subject>Thalidomide - adverse effects</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkMtKAzEUhoMotlYXvoAMuLHItLnOZWcZqxUKbnQdkplMm9JmxmQG6c538A19ElOndSeYTQ7h-0_O-QC4RHCE_BnnqhghijE7An1EIhZiTOAx6EMC4zBKSdIDZ86tIEQExewU9AhGaZJS1gd3k9qqjV4L1wTaBFIZvTBBvrSV0XlQq0291IvWBTczoddq-_Xx2RVBoZ0STg3PwUkp1k5d7O8BeH2YvmSzcP78-JRN5mFOMGShwComiYwYTgpECoSEIDIWcZKWgsqkpJCKXJQRVVTCVFCUSpkKn5AsErKEZACuu761rd5a5Rq-qlpr_Jcc-9X9kimNPTXsqNxWzllV8trqjbBbjiDfueLeFf9x5dmrfcdWbvzrgTzI8UDSAe9KVqXLtTK5-sUghIxQwiLqK4gy3YhGVyarWtP46O3_o54e7-md2r9H5tn0vpv9G0twk1w</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Riquelme‐Mc Loughlin, C.</creator><creator>Iranzo, P.</creator><creator>Mascaró, J.M.</creator><general>Wiley</general><general>Oxford University Press</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-5385-127X</orcidid><orcidid>https://orcid.org/0000-0001-9327-2555</orcidid></search><sort><creationdate>202008</creationdate><title>Apremilast in benign chronic pemphigus (Hailey–Hailey disease)</title><author>Riquelme‐Mc Loughlin, C. ; Iranzo, P. ; Mascaró, J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3205-a2e738b6528d13d11aa3b7a789fa4b8f404acaf64e4b09a419bb9a38bb56abf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Autoimmune diseases</topic><topic>Chronic Disease</topic><topic>Dermatology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pemphigus</topic><topic>Pemphigus, Benign Familial - drug therapy</topic><topic>Pemphigus, Benign Familial - genetics</topic><topic>Pemphigus, Benign Familial - pathology</topic><topic>Phosphodiesterase 4 Inhibitors - administration & dosage</topic><topic>Phosphodiesterase 4 Inhibitors - adverse effects</topic><topic>Phosphodiesterase 4 Inhibitors - therapeutic use</topic><topic>Quality of Life</topic><topic>Science & Technology</topic><topic>Severity of Illness Index</topic><topic>Skin diseases</topic><topic>Thalidomide - administration & dosage</topic><topic>Thalidomide - adverse effects</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riquelme‐Mc Loughlin, C.</creatorcontrib><creatorcontrib>Iranzo, P.</creatorcontrib><creatorcontrib>Mascaró, J.M.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riquelme‐Mc Loughlin, C.</au><au>Iranzo, P.</au><au>Mascaró, J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apremilast in benign chronic pemphigus (Hailey–Hailey disease)</atitle><jtitle>Clinical and experimental dermatology</jtitle><stitle>CLIN EXP DERMATOL</stitle><addtitle>Clin Exp Dermatol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>45</volume><issue>6</issue><spage>737</spage><epage>739</epage><pages>737-739</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>32198945</pmid><doi>10.1111/ced.14225</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-5385-127X</orcidid><orcidid>https://orcid.org/0000-0001-9327-2555</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2020-08, Vol.45 (6), p.737-739 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_journals_2422938947 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Alma/SFX Local Collection |
| subjects | Adult Autoimmune diseases Chronic Disease Dermatology Female Follow-Up Studies Humans Life Sciences & Biomedicine Male Middle Aged Pemphigus Pemphigus, Benign Familial - drug therapy Pemphigus, Benign Familial - genetics Pemphigus, Benign Familial - pathology Phosphodiesterase 4 Inhibitors - administration & dosage Phosphodiesterase 4 Inhibitors - adverse effects Phosphodiesterase 4 Inhibitors - therapeutic use Quality of Life Science & Technology Severity of Illness Index Skin diseases Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use Treatment Outcome |
| title | Apremilast in benign chronic pemphigus (Hailey–Hailey disease) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T02%3A42%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apremilast%20in%20benign%20chronic%20pemphigus%20(Hailey%E2%80%93Hailey%20disease)&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Riquelme%E2%80%90Mc%20Loughlin,%20C.&rft.date=2020-08&rft.volume=45&rft.issue=6&rft.spage=737&rft.epage=739&rft.pages=737-739&rft.issn=0307-6938&rft.eissn=1365-2230&rft_id=info:doi/10.1111/ced.14225&rft_dat=%3Cproquest_webof%3E2422938947%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2422938947&rft_id=info:pmid/32198945&rfr_iscdi=true |